Kalbe Farma Tbk PT (KLBF.JK) Stock Price
Kalbe Farma Tbk PT Price
Revenue has compounded at 9.7% per year over the past 19 years to 35.32 T IDR. Earnings per share have grown at 9.2% per year over the last 19 years. Kalbe Farma Tbk PT's net margin stands at 10.4%, down from 12.1% several years earlier. Kalbe Farma Tbk PT currently offers a dividend yield of about 5.00%. The payout ratio is around 45% of earnings. The dividend has grown at 17.4% per year over the past 18 years. Analysts set a median price target of 1,652.40 IDR, implying 129.5% above the current price. Of 18 analysts, 15 rate the stock a buy — an overall Buy consensus.
Kalbe Farma Tbk PT stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Kalbe Farma Tbk PT business model & stock analysis
Frequently asked questions about Kalbe Farma Tbk PT
The business model of Kalbe Farma Tbk PT is focused on the healthcare industry. As one of the largest pharmaceutical companies in Indonesia, Kalbe Farma Tbk PT operates through various segments, including Prescription Pharmaceuticals, Consumer Health, and Distribution & Logistics. Their business model relies on research and development, manufacturing, marketing, and distribution of a wide range of pharmaceutical products, such as medicines, vitamins, supplements, and health foods. By providing quality and affordable healthcare solutions, Kalbe Farma Tbk PT aims to improve the well-being of individuals and contribute to the overall health of the community.
Kalbe Farma Tbk PT is primarily active in the pharmaceutical industry.
The main competitors of Kalbe Farma Tbk PT in the market include companies such as Sanbe Farma, Dexa Medica, Kimia Farma, and Tempo Scan Pacific.
Kalbe Farma Tbk PT is a leading pharmaceutical company based in Indonesia. Founded in 1966, Kalbe Farma has since grown to become one of the largest and most successful healthcare enterprises in the country. With a strong focus on research and development, the company continuously strives to provide innovative and high-quality products to meet the diverse needs of its customers. Kalbe Farma's extensive range of pharmaceuticals, nutritional products, and over-the-counter drugs cater to various therapeutic areas. Over the years, the company has garnered a strong reputation for its commitment to excellence and its contribution to improving the healthcare sector in Indonesia.
Kalbe Farma Tbk PT has achieved several significant milestones over the years. The company has successfully established itself as a leading pharmaceutical and healthcare provider in Indonesia. It has expanded its product portfolio, offering a wide range of quality medicines, nutritional products, and health supplements. Kalbe Farma Tbk PT has also made significant advancements in research and development, introducing innovative solutions and improving healthcare access for the Indonesian population. The company's strong focus on technology and digitalization has further propelled its growth and reach. With its commitment to excellent customer service and continuous improvement, Kalbe Farma Tbk PT continues to thrive in the highly competitive pharmaceutical industry.
Kalbe Farma Tbk PT is primarily present in Indonesia.
Kalbe Farma Tbk PT is a leading pharmaceutical company that upholds strong values and a well-defined corporate philosophy. With a commitment to excellence and a focus on innovation, Kalbe Farma Tbk PT strives to improve the health and well-being of individuals and communities. The company believes in providing high-quality healthcare solutions that are accessible, affordable, and sustainable. Kalbe Farma Tbk PT also places great importance on ethical conduct, transparency, and accountability in its operations. Through its dedication to continuous improvement and customer satisfaction, Kalbe Farma Tbk PT has earned a reputation as a trusted and reliable provider of pharmaceutical products and services.
Analysts currently set an average price target of 1,685.35 IDR for the Kalbe Farma Tbk PT stock (median: 1,652.40 IDR), implying +132.5 % versus the latest price. The consensus is based on 18 analyst ratings.
19 analysts currently rate the Kalbe Farma Tbk PT stock: 16 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Kalbe Farma Tbk PT to generate revenue of 38.88 T IDR and earnings per share of 81.38 IDR.
Converted at the current exchange rate, the Kalbe Farma Tbk PT share trades at 0.04 EUR (720.00 IDR).
The Kalbe Farma Tbk PT share (KLBF.JK) is listed on 4 stock exchanges, including: Frankfurt (LCLA.F), München (LCLA.MU).
Kalbe Farma Tbk PT is the largest pharmaceutical company in Indonesia and is one of the leading Southeast Asian companies in the healthcare industry. The company was founded in 1966 and has since built a portfolio of over 1,500 products. Kalbe Farma offers a wide range of products and services in the health, nutrition, and wellness sectors. The different divisions of Kalbe Farma include pharmaceuticals, dietary supplements, healthcare products, diagnostics, and medical equipment. In the pharmaceutical division, the company produces antibiotics, antivirals, vitamins, cardiovascular medications, and hormones, among others. Kalbe Farma's dietary supplements include vitamins, minerals, and herbal products that contribute to health and well-being. The company also has a wide range of healthcare products that contain therapeutic support and health-promoting ingredients. These include cosmetic products or care items for individuals with diabetes or other specific health problems. The company's diagnostics division offers a specialized portfolio of medical laboratory equipment and services for diagnosis and research. In the medical equipment division, Kalbe Farma offers endoscopic systems for gastroenterological examinations and ventilation-related medical equipment for healthcare facilities. Kalbe Farma also operates a number of subsidiaries and joint ventures that focus on specialized services and products for specific target groups. Among other things, the company has a range of investments in the animal health and animal products sector. Kalbe Farma's business model has several success factors. The company has comprehensive expertise in the production and development of healthcare products for a wide range of applications. Due to its size, flexibility, and product diversity, Kalbe Farma is able to cover a broad range of customer needs. The company is also heavily involved in research and development to ensure that it stays at the forefront of medical innovation. Another strength of the company is its ability to constantly renew its portfolio and adapt to the changing needs of the market. This is achieved, for example, through the continuous introduction of new products, services, and technologies that offer customers high quality and effectiveness. Overall, Kalbe Farma has a strong business model with a wide range of products and services and a strong focus on scientific research and innovation. The company also has a strong presence in Southeast Asia and is therefore able to serve various needs of the rapidly growing healthcare markets in this region.
The expected revenue of Kalbe Farma Tbk PT is 38.88 T IDR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Kalbe Farma Tbk PT is 3.70 T IDR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Kalbe Farma Tbk PT is currently 8.85. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Kalbe Farma Tbk PT stock.
The price-to-sales ratio (P/S) of Kalbe Farma Tbk PT is currently 0.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Kalbe Farma Tbk PT stock.
The Eulerpool Quality Score for Kalbe Farma Tbk PT is 7/10.
The ISIN of Kalbe Farma Tbk PT is ID1000125107. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Kalbe Farma Tbk PT is A1J5U9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Kalbe Farma Tbk PT is KLBF.JK. The ticker symbol is used to trade Kalbe Farma Tbk PT shares on the stock exchange.
Kalbe Farma Tbk PT stock
Kalbe Farma Tbk PT Peer Group
Kalbe Farma Tbk PT Ticker
Kalbe Farma Tbk PT FIGI
All fundamentals and in-depth analysis of Kalbe Farma Tbk PT
Our stock analysis for Kalbe Farma Tbk PT stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kalbe Farma Tbk PT. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.